Bluebird Bio has been granted the go-ahead to market its gene therapy for the blood disorder β-thalassemia. Zynteglo gained conditional market approval from the European Commission in June to treat transfusion-dependent β-thalassemia in patients 12 years and older who have no other treatment options.
Image by lisichik from Pixabay
Read more at Nature…
The post First gene therapy for β-thalassemia approved appeared first on Healthier Environment Living Program.